Roivant Sciences Ltd
F:87S
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Roivant Sciences Ltd
Roivant Sciences Ltd
Research & Development
Roivant Sciences Ltd
Research & Development Peer Comparison
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Roivant Sciences Ltd
F:87S
|
Research & Development
-$528.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$124.4m
|
CAGR 3-Years
-137%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Research & Development
-$122.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Research & Development
-$159.2m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Research & Development
-£163.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Roivant Sciences Ltd's Research & Development?
Research & Development
-528.2m
USD
Based on the financial report for Mar 31, 2024, Roivant Sciences Ltd's Research & Development amounts to -528.2m USD.
What is Roivant Sciences Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
14%
Over the last year, the Research & Development growth was 15%. The average annual Research & Development growth rates for Roivant Sciences Ltd have been 14% over the past three years .
You don't have any saved screeners yet
